Prognostic significance, angiographic characteristics and impact of antithrombotic and anticoagulant therapy on outcomes in high versus low grade coronary artery ectasia: A long-term follow-up study.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 02 06 2018
accepted: 23 09 2018
pubmed: 6 11 2018
medline: 23 6 2020
entrez: 6 11 2018
Statut: ppublish

Résumé

To assess the prognostic significance of high vs. low grade coronary artery ectasia (CAE) and the impact of antithrombotic or anticoagulant therapy on adverse cardiac outcomes. There is paucity of knowledge on the impact of angiographic characteristics in CAE or that of antithrombotic or anticoagulant therapy on outcomes. In this retrospective study, we reviewed angiograms and medical records of all cases of confirmed CAE (2001-2011). Extent of CAE was categorized using the Markis classification. Types 1 and 2 were categorized as high-grade and types 3 and 4 as low-grade CAE. Angiographic flow was recorded as normal or sluggish (<TIMI 3). Outcomes assessed were acute coronary syndromes and all-cause mortality on follow-up. The study included 317 patients with CAE (mean follow-up of 9.7 ± 2.3 years). High-grade CAE (n = 151) had a significantly higher incidence of ACS on follow-up (41% vs. 30%, P = 0.01; OR 2.0, CI 1.3-3.3, P = 0.01) despite similar underlying CAD. Sluggish coronary flow (irrespective of CAE grade) was also associated with a higher incidence of ACS (45% vs. 28%, P < 0.01; OR 2.25, CI 1.4-3.6, P = 0.01). Presence of both sluggish flow and high-grade CAE had an additive effect on occurrence of ACS (OR 4, CI 2.0-7.8, P < 0.01). Neither sluggish flow nor high-grade CAE were associated with mortality. Dual-antiplatelet therapy (DAPT) or use of oral anticoagulation was associated with a reduced incidence of ACS (17% vs. 34%, P = 0.03 and 29% vs. 42%, P = 0.02, respectively). The angiographic extent of CAE and sluggish coronary flow are independent predictors of future ACS despite good medical management. DAPT or oral anticoagulation reduces the risk of future ACS.

Sections du résumé

OBJECTIVES
To assess the prognostic significance of high vs. low grade coronary artery ectasia (CAE) and the impact of antithrombotic or anticoagulant therapy on adverse cardiac outcomes.
BACKGROUND
There is paucity of knowledge on the impact of angiographic characteristics in CAE or that of antithrombotic or anticoagulant therapy on outcomes.
METHODS AND RESULTS
In this retrospective study, we reviewed angiograms and medical records of all cases of confirmed CAE (2001-2011). Extent of CAE was categorized using the Markis classification. Types 1 and 2 were categorized as high-grade and types 3 and 4 as low-grade CAE. Angiographic flow was recorded as normal or sluggish (<TIMI 3). Outcomes assessed were acute coronary syndromes and all-cause mortality on follow-up. The study included 317 patients with CAE (mean follow-up of 9.7 ± 2.3 years). High-grade CAE (n = 151) had a significantly higher incidence of ACS on follow-up (41% vs. 30%, P = 0.01; OR 2.0, CI 1.3-3.3, P = 0.01) despite similar underlying CAD. Sluggish coronary flow (irrespective of CAE grade) was also associated with a higher incidence of ACS (45% vs. 28%, P < 0.01; OR 2.25, CI 1.4-3.6, P = 0.01). Presence of both sluggish flow and high-grade CAE had an additive effect on occurrence of ACS (OR 4, CI 2.0-7.8, P < 0.01). Neither sluggish flow nor high-grade CAE were associated with mortality. Dual-antiplatelet therapy (DAPT) or use of oral anticoagulation was associated with a reduced incidence of ACS (17% vs. 34%, P = 0.03 and 29% vs. 42%, P = 0.02, respectively).
CONCLUSION
The angiographic extent of CAE and sluggish coronary flow are independent predictors of future ACS despite good medical management. DAPT or oral anticoagulation reduces the risk of future ACS.

Identifiants

pubmed: 30393992
doi: 10.1002/ccd.27929
doi:

Substances chimiques

Anticoagulants 0
Fibrinolytic Agents 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1219-1227

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Prasad Gunasekaran (P)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Dusan Stanojevic (D)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Taylor Drees (T)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

John Fritzlen (J)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Megan Haghnegahdar (M)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Matthew McCullough (M)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Rajat Barua (R)

Division of Cardiology, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri.

Ashwani Mehta (A)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Eric Hockstad (E)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Mark Wiley (M)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Matthew Earnest (M)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Peter Tadros (P)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Randall Genton (R)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Kamal Gupta (K)

Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH